<DOC>
	<DOCNO>NCT02953860</DOCNO>
	<brief_summary>A phase 2 study evaluate tolerability clinical activity add enzalutamide fulvestrant treatment woman advance breast cancer ER and/or PR positive Her2 normal .</brief_summary>
	<brief_title>Fulvestrant Plus Enzalutamide ER+/Her2- Advanced Breast Cancer</brief_title>
	<detailed_description>This single arm , non-randomized , open-label phase 2 study design evaluate tolerability clinical activity add enzalutamide fulvestrant treatment woman advance breast cancer ER and/or PR-positive Her2 normal . In study 500 mg Fulvestrant give IM day 1 , 15 , 28 , every 4 week per standard care ( SOC ) 160mg Enzalutamide , conjunction Fulvestrant , PO daily .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>ER+ Her2 breast cancer Metastatic At least 18 year age Candidate fulvestrant therapy patient start fulvestrant may enter trial within 3 month start fulvestrant Measurable Evaluable RECIST 1.1 PS 02 Able swallow study drug comply study requirement Tumor available fresh biopsy ( two biopsy pretreatment regard enzalutamide , treatment @ 4 week ) . ( The patient ask would willing provide third biopsy time progression ) Patients may already get load dos fulvestrant and/or ovarian suppression If patient pre peri menopausal , need concurrent ovarian suppression . ANC &gt; 1000/uL , platelet &gt; 75,000/uL screen visit Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) screen visit unless alternate nonmalignant etiology exists ( eg , Gilbert 's disease ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 time ULN &lt; 5 time ULN patient document liver metastasis Creatinine &lt; 1.5 time ULN INR &lt; 1.5 time ULN , warfarin , safely transition biopsy Willing donate blood research 4 time point Written inform consent obtain prior biopsy blood sample Current previously treat brain leptomeningeal metastases History seizures Prior treatment antiandrogen ( abiraterone , ARN509 , bicalutamide , enzalutamide , ODM201 , TAK448 , TAK683 , TAK700 , VT464 ) . Systemic estrogen androgen within 14 day initiate therapy . Vaginal estrogen allow necessary patient comfort .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>101 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>ER+/Her2 Advanced Breast Cancer</keyword>
</DOC>